BioSpace News Archive

Astellas Pharma US, Inc. announced that the U.S. Food and Drug Administration has accepted the company’s supplemental New Drug Application for CRESEMBA®, a prodrug of isavuconazole, an azole antifungal drug, seeking approval for the treatment of invasive aspergillosis or invasive mucormycosis in pediatric patients aged one to 17 years old.

180 Life Sciences Corp., a clinical-stage biotechnology company, announced the pricing of a public offering of 4,615,385 shares of the Company’s common stock and warrants to purchase up to 4,615,385 shares of common stock at a purchase price per share of $0.65.

Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that it has received approval from the Israeli Ministry of Health, Medical Device Division (known as “AMAR”) to initiate commercial sales of the Pure-Vu® EVS System in Israel.

Inspira Technologies OXY B.H.N. Ltd., a company aiming to revolutionize acute respiratory care, announced its financial results for the second quarter ended June 30, 2023.

Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced second quarter financial results for 2023 and provided a corporate update on its development programs.

Zynex, Inc., an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced that, since its founding, the company has treated more than 1 million patients through its pain management division.

Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, highlighted pipeline progress and reported second quarter 2023 financial results.

Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced business highlights and reported financial results for the second quarter ended June 30, 2023.

KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced four recent executive appointments to continue its momentum and vision of becoming a next-generation CDMO.

Vaccitech plc announced its financial results for the second quarter of 2023 and provided an overview of the Company’s progress.